SYS-CON MEDIA Authors: Roberto Medrano, Dmitriy Stepanov, Gilad Parann-Nissany, Srinivasan Sundara Rajan, Sean Houghton

News Feed Item

Cyberonics Reports Fiscal 2015 First Quarter Results

Year-on-year sales increase for the 25th consecutive quarter

HOUSTON, Aug. 21, 2014 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX) today announced results for the quarter ended July 25, 2014. 

Quarterly highlights1 

Operating results for the first quarter of fiscal 2015 compared to the first quarter of fiscal 2014, and other achievements, include:

  • Worldwide net product sales of $72.0 million, an increase of 6.8%;
  • Strong international net sales of $13.2 million, an increase of 14.5% on a constant currency basis;
  • U.S. net product sales reached a new high of $58.8 million, an increase of 4.4% over the comparable quarter of the prior year;
  • Income from operations of $22.0 million increased by 12.4% from an adjusted income from operations in the prior year of $19.6 million;
  • Adjusted non-GAAP income per diluted share of $0.53 compared with adjusted non-GAAP income per diluted share of $0.45, an increase of 18%;
  • Submission of the ProGuardianREST in-home seizure monitoring system to the Food and Drug Administration ("FDA") for regulatory clearance;
  • Submission of the first module, comprising clinical data, to support eventual CE mark approval of the VITARIA™ system (Autonomic Regulation Therapy for chronic heart failure);
  • Discussions with the FDA to agree on next steps for U.S. regulatory process of the AspireSR® generator; and
  • Receipt of initial regulatory approvals for the new manufacturing facility in Costa Rica.

1

The financial and operating results for the thirteen weeks ended July 25, 2014 and July 26, 2013 include and exclude certain items for the purposes of non-GAAP comparisons. As discussed below under "Use of Non-GAAP Financial Measures" in this release, the company refers to and makes comparisons with certain non-GAAP financial measures. Investors should consider non-GAAP measures in addition to, and not as a substitute for or superior to, financial performance measures prepared in accordance with GAAP. Please refer to the attached non-GAAP reconciliation. Numbers may be affected by rounding.

Results and objectives

"Cyberonics continued to deliver increased sales and earnings during our first quarter of fiscal 2015 over the same quarter last year," commented Dan Moore, President and Chief Executive Officer.  "However, overall net sales for the quarter fell short of our expectations by approximately $1 million.  The softness was in our U.S. business, where unit sales grew by 2%, and net sales increased by 4% over the comparable period in the prior year to a new high of $58.8 million.  We have not yet reestablished year-on-year growth in new patient adoption.  While we expect greater productivity in the second quarter from our new field sales employees, the entire Cyberonics U.S. commercial team remains focused on restoring new patient growth.  The team has implemented additional initiatives for the second quarter targeting comprehensive epilepsy centers and physicians who have been inconsistent in their utilization of VNS Therapy.  We remain optimistic about the potential for VNS Therapy in this underserved market.  As mentioned last quarter, we are increasing our investment in sales and marketing significantly for fiscal 2015.

"International sales showed consistent growth with unit sales increasing by 14% and net sales of $13.2 million increasing by 14% on a constant currency basis.  Again this quarter, Europe and Latin America led the growth with solid country performances throughout their respective regions.  The continuation of our limited market launch of the AspireSR generator in the U.K. and Germany is in line with our expectations.  Several accounts have reordered the product, and penetration of the AspireSR generator in these countries is estimated at 17%, and has been accompanied by a price increase.

"VNS Therapy implants in Japan grew by an estimated 20% over the same quarter in the prior year.  If this level of growth is sustained, Japan will become one of our larger single-country markets this fiscal year.  We previously discussed our plan to hire direct employees in that country, and we now expect to hire the first of these new employees by the end of the second quarter.

"We have had constructive discussions with the FDA to ascertain next steps for U.S. approval for the AspireSR generator.  While we are encouraged by this progress and are not planning another study to support the U.S. regulatory submission, approval could still require further clinical work.  The AspireSR generator is the first closed-loop VNS Therapy System, and is an important addition to our product portfolio, providing physicians and patients with another foundational treatment option for drug-resistant epilepsy, as we have already seen in the European limited launch.

"We continue to make progress on the ProGuardian platform, with a recent FDA regulatory submission of ProGuardianREST.  We anticipate a limited market launch in Europe in our fiscal third quarter.  We continue to anticipate regulatory submissions for our Centro generator in the current fiscal year.

"Dr. Inder Anand, Professor of Medicine at the University of Minnesota and chair of the ANTHEM-HF clinical study steering committee, will present the results of our ANTHEM-HF clinical study of Autonomic Regulation Therapy for chronic heart failure at the European Society of Cardiology meeting on September 1.  Regulatory submission to obtain a CE Mark is now underway with the recent submission of the first module.  We expect to complete the submission before the end of the calendar year," concluded Mr. Moore.

Stock Repurchase Update

Cyberonics purchased 189,000 shares on the open market in the first quarter of fiscal 2015, leaving 551,000 shares for repurchase under the current authorization.  We expect to complete this program by the end of fiscal year 2015.

Fiscal 2015 guidance

Cyberonics is reaffirming guidance for fiscal 2015 as follows:

Net sales are expected to be in the range of $300 million to $307 million. The assumptions used in setting this range include:

  • Growth of approximately 10%, after adjusting fiscal 2014 for the single country order of $4.7 million, and the final recognition of license revenue of $1.5 million;
  • Worldwide unit growth of approximately 7%;
  • Low to mid-single-digit growth in U.S. new patient implants, an adjustment to our prior assumption;
  • Mid-single-digit growth in U.S. replacement implants;
  • Continued international sales growth in the low to mid-teens; and
  • Euro/Dollar exchange rate of $1.35.

Gross profit margin is expected to be between 90.0% and 91.0%.

Income from operations is expected to be in the range of $96 million to $99 million.  The company anticipates an adjusted effective tax rate of approximately 35% for fiscal 2015, which assumes the renewal of the R & D tax credit.

Adjusted net income for fiscal 2015 is expected to be in the range of $62 million to $64 million.

The company expects adjusted diluted earnings per share (EPS) will be in the range of $2.33 to $2.39.

Please refer to the table on the last page of this release.

Additional details will be provided during today's conference call and in an investor presentation, which is available in the investor relations section of Cyberonics' corporate website at http://www.cyberonics.com.

Use of non-GAAP financial measures

In this press announcement, management has disclosed financial measurements that present financial information not in accordance with Generally Accepted Accounting Principles (GAAP).  These measurements are not a substitute for GAAP measurements, although company management uses these measurements as aids in monitoring the company's ongoing financial performance quarter to quarter and year to year on a regular basis and for benchmarking against other medical technology companies.  Adjusted non-GAAP income from operations, adjusted non-GAAP net income and adjusted non-GAAP income per diluted share measure the income from operations, net income and income per diluted share of the company including and excluding items management consider to be unusual.  Management uses and presents these measures because management believes that they facilitate an understanding of the financial impact of unusual items on the company's short- and long-term financial trends.  Management also uses adjusted non-GAAP items to forecast and to evaluate the operational performance of the company, as well as to compare results of current periods to prior periods on a consistent basis.  Adjusted earnings before interest, tax, depreciation and amortization (EBITDA) measures the adjusted non-GAAP income from operations of the company and excludes the aforementioned items, as well as non-cash equity compensation and other income (expense) items.

Non-GAAP financial measures used by the company may be calculated differently from, and therefore may not be comparable to, similarly-titled measures used by other companies.  Investors should consider non-GAAP measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.

Please refer to the attached reconciliations between GAAP and non-GAAP financial measures.

First-Quarter Results Webcast and Conference Call Instructions

Cyberonics will host a conference call today, August 21, 2014, beginning at 8:00 a.m. Central Time (9:00 a.m. Eastern Time) to review its results of operations for the fiscal year 2015 first quarter, followed by a question and answer session.

The conference call will be available to interested parties through a live audio webcast in the investor relations section of Cyberonics' corporate website at www.cyberonics.com.  To listen to the conference call live by telephone, dial 877-638-4557 (if dialing from within the U.S.) or 914-495-8522 (if dialing from outside the U.S.).  The conference ID is 76419439.

Within 24 hours of the webcast, a replay will be available under the "Events & Presentations" section of the Investor Relations portion of the Cyberonics website, where it will be archived and accessible for approximately 12 months.

About Cyberonics, Inc. and the VNS Therapy® System

Cyberonics, Inc. is a medical technology company with core expertise in neuromodulation.  The company developed and markets the VNS Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression.  The VNS Therapy System uses an implanted medical device that delivers pulsed electrical signals to the vagus nerve.  Cyberonics offers the VNS Therapy System in selected markets worldwide.

Additional information on Cyberonics and the VNS Therapy System is available at www.cyberonics.com.

Safe harbor statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended.  These statements can be identified by the use of forward-looking terminology, including "may," "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or other similar words.  Statements contained in this press release are based on information presently available to us and assumptions that we believe to be reasonable.  We are not assuming any duty to update this information if those facts change or if we no longer believe the assumptions to be reasonable.  Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning increasing our epilepsy market penetration and sales growth, completing product development work, conducting and completing clinical studies, applying for and obtaining regulatory approvals, launching new commercial products, completing our share repurchase program and achieving our financial guidance for fiscal 2015.  Our actual results may differ materially.  Important factors that may cause actual results to differ include, but are not limited to: continued market acceptance of the VNS Therapy System and sales of our products; the development and satisfactory completion of clinical studies; the achievement of regulatory approval for new products, including use of the VNS Therapy System for the treatment of other indications; satisfactory completion of the post-market registry required by the U.S. Food and Drug Administration as a condition of approval for the treatment-resistant depression indication; adverse changes in coverage or reimbursement amounts by the Centers for Medicare & Medicaid Services, state Medicaid agencies and private insurers; the presence or absence of intellectual property protection and potential infringement claims; maintaining compliance with government regulations; product liability claims and potential litigation; reliance on single suppliers and manufacturers for certain components; the accuracy of management's estimates of future expenses and sales; the potential identification of material weaknesses in our internal controls over financial reporting; and other risks detailed from time to time in our filings with the Securities and Exchange Commission (SEC).  For a detailed discussion of these and other cautionary statements, please refer to our most recent filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended April 25, 2014.

Contact information

Greg Browne, CFO
Cyberonics, Inc.
100 Cyberonics Blvd.
Houston, TX 77058
Main:  (281) 228-7262
Fax:  (281) 218-9332
[email protected]

 

 

CYBERONICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)




 For the Thirteen Weeks Ended



July 25, 2014


July 26, 2013








Net sales


$

72,003,966



$

68,872,357


Cost of sales



6,410,392




6,544,033


Gross profit



65,593,574




62,328,324


Operating expenses:









Selling, general and administrative



33,027,606




29,306,271


Research and development



10,562,754




11,975,165


Litigation settlement



––




7,442,847


Total operating expenses



43,590,360




48,724,283


Income from operations



22,003,214




13,604,041


Interest income, net



37,666




43,415


Other income (expense), net



171,455




(130,691)


Income before income tax



22,212,335




13,516,765


Income tax expense



8,693,513




4,842,839


Net income


$

13,518,822



$

8,673,926











Basic income per share


$

0.51



$

0.32


Diluted income per share


$

0.50



$

0.31











Shares used in computing basic income per share



26,674,134




27,513,191


Shares used in computing diluted income per share



26,915,388




27,845,495


 

CYBERONICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited except where indicated)




July 25, 2014


April 25, 2014






(Audited)


ASSETS









Current Assets







Cash and cash equivalents


$

107,679,362



$

103,299,116


Short-term investments



25,047,700




25,028,957


Accounts receivable, net



48,297,114




50,674,041


Inventories



18,685,693




17,630,111


Deferred tax assets



9,446,096




17,208,365


Other current assets



5,941,944




6,590,612


Total Current Assets



215,097,909




220,431,202


Property, plant and equipment, net



40,088,068




39,534,873


Intangible assets, net



11,329,978




11,654,690


Long-term investments



15,944,427




15,944,427


Deferred tax assets



6,218,609




5,770,644


Other assets



1,244,242




855,558


Total Assets


$

289,923,233



$

294,191,394




















LIABILITIES AND STOCKHOLDERS' EQUITY











Current Liabilities









Accounts payables and accrued liabilities


$

24,150,468



$

29,897,697


Total Current Liabilities



24,150,468




29,897,697


Long-term Liabilities



1,448,860




5,193,853


Total Liabilities



25,599,328




35,091,550


Total Stockholders' Equity



264,323,905




259,099,844


              Total Liabilities and Stockholders' Equity


$

289,923,233



$

294,191,394


 


CYBERONICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)




For the Thirteen Weeks Ended




July 25, 2014




July 26, 2013











Cash Flow From Operating Activities:









Net income


$

13,518,822



$

8,673,926


Non-cash items included in net income:









Depreciation



1,235,902




1,010,839


Amortization



324,712




346,162


Stock-based compensation



3,512,443




3,153,499


Deferred income tax



3,402,023




(483,988)


Deferred license revenue amortization



-




(1,467,869)


Other



(160,061)




(13,497)


Changes in operating assets and liabilities:









Accounts receivable, net



2,129,438




(366,782)


Inventories



(1,057,344)




149,041


Litigation settlement



-




7,111,090


Other current and non-current assets



238,129




424,453


Other current and non-current liabilities



(5,046,273)




(9,049,218)


Net cash provided by operating activities



18,097,791




9,487,656


Cash Flow From Investing Activities:









Short-term investments



6,459




(10,300,129)


Intangible asset purchases



-




(1,250,000)


Purchases of property, plant and equipment



(1,815,500)




(5,533,847)


Net cash used in investing activities



(1,809,041)




(17,083,976)


Cash Flow From Financing Activities:









Proceeds from exercise of options for common stock



1,509,758




2,613,639


Cash settlement of stock units



(786,361)




(936,115)


Purchase of treasury stock



(13,782,231)




(12,964,495)


Realized excess tax benefit



1,264,795




4,474,196


Net cash used in financing activities



(11,794,039)




(6,812,775)


Effect of exchange rate changes on cash and cash equivalents



(114,465)




22,358


Net increase (decrease) in cash and cash equivalents



4,380,246




(14,386,737)


Cash and cash equivalents at beginning of period



103,299,116




120,708,572


Cash and cash equivalents at end of period


$

107,679,362



$

106,321,835


 

 


RECONCILIATION BETWEEN GAAP AND NON-GAAP FINANCIAL MEASURES

 (Unaudited)


The following table sets forth the reconciliation between GAAP income from operations and adjusted non-GAAP income from operations (unaudited):




For the Thirteen Weeks Ended



July 25, 2014


July 26, 2013










Income from operations


$

22,003,214



$

13,604,041


License fee(1)



-




(1,467,869)


Litigation settlement



-




7,442,847


Adjusted non-GAAP income from operations


$

22,003,214



$

19,579,019


 

The following tables set forth the reconciliation between GAAP and our non-GAAP financial measures for net income and diluted income per share (unaudited):




For the Thirteen Weeks Ended



July 25, 2014


July 26, 2013










Net income


$

13,518,822



$

8,673,926


License fee, net of tax (1)



-




(920,869)


Litigation settlement, net of tax



-




4,776,075


Tax expense associated with change in international structure



587,670




-


Benefit assumed from extension of R&D tax credit (2)



217,436




-


Adjusted non-GAAP net income


$

14,323,928



$

12,529,132




















Diluted income per share


$

0.50



$

0.31


License fee, net of tax (1)



-




(0.03)


Litigation settlement, net of tax



-




0.17


Tax expense associated with change in international structure



0.02




-


Benefit assumed from extension of R&D tax credit (2)



0.01




-


Adjusted non-GAAP diluted income per share (3)


$

0.53



$

0.45




(1)

Completion of license fee recognition.

(2)

Consistent with annual guidance and prior year.

(3)

Numbers may be affected by rounding.








For the Thirteen Weeks Ended



July 25, 2014


July 26, 2013










Adjusted non-GAAP net income


$

14,323,928



$

12,529,132


Interest income, net



(37,666)




(43,415)


Other (income) expense, net



(171,455)




130,691


Depreciation and amortization



1,560,614




1,357,001


Stock based compensation



3,512,443




3,153,499


Income tax expense – adjusted for the income tax impact of non-GAAP items



7,888,407




6,962,611


Adjusted EBITDA


$

27,076,271



$

24,089,519


 

 


NET SALES

Fiscal 2014 and Guidance for Fiscal 2015

($000s)



Fiscal 2014

 


Growth over

Fiscal 2013


Fiscal 2015

Mid-Point


Growth over

Fiscal 2014


Fiscal 2015

Guidance Range


Range of Growth

over Fiscal 2014

























U.S.

$

225,455


7.9

%


$

247,500


9.8

%


$

245,000

-

$

250,000


8.7

%

-

10.9

%

























International


50,345


14.5

%



56,000


11.2

%



55,000

-


57,000


9.2

%

-

13.2

%

























Net sales(1)

$

275,800


9.1

%


$

303,500


10.0

%


$

300,000

-

$

307,000


8.8

%

-

11.3

%

























Single country order

$

4,746


N/A



$

-


N/A






































Net product sales

$

280,546


11.0

%


$

303,500


8.2

%


$

300,000

-

$

307,000


6.9

%

-

9.4

%

























Licensing revenue

$

1,468


-1.7

%


$

-


N/A






































Net sales

$

282,014


10.9

%


$

303,500


7.6

%


$

300,000

-

$

307,000


6.4

%

-

8.9

%



(1)

Net product sales excluding single country order

SOURCE Cyberonics, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The 3rd International @ThingsExpo, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that it is now accepting Keynote Proposals. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devices - computers, smartphones, tablets, and sensors - connected to th...
"There is a natural synchronization between the business models, the IoT is there to support ,” explained Brendan O'Brien, Co-founder and Chief Architect of Aria Systems, in this SYS-CON.tv interview at the 15th International Cloud Expo®, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
The term culture has had a polarizing effect among DevOps supporters. Some propose that culture change is critical for success with DevOps, but are remiss to define culture. Some talk about a DevOps culture but then reference activities that could lead to culture change and there are those that talk about culture change as a set of behaviors that need to be adopted by those in IT. There is no question that businesses successful in adopting a DevOps mindset have seen departmental culture change, ...
The Internet of Things promises to transform businesses (and lives), but navigating the business and technical path to success can be difficult to understand. In his session at @ThingsExpo, Sean Lorenz, Technical Product Manager for Xively at LogMeIn, demonstrated how to approach creating broadly successful connected customer solutions using real world business transformation studies including New England BioLabs and more.
The security devil is always in the details of the attack: the ones you've endured, the ones you prepare yourself to fend off, and the ones that, you fear, will catch you completely unaware and defenseless. The Internet of Things (IoT) is nothing if not an endless proliferation of details. It's the vision of a world in which continuous Internet connectivity and addressability is embedded into a growing range of human artifacts, into the natural world, and even into our smartphones, appliances, a...
SYS-CON Media announced that Centrify, a provider of unified identity management across cloud, mobile and data center environments that delivers single sign-on (SSO) for users and a simplified identity infrastructure for IT, has launched an ad campaign on Cloud Computing Journal. The ads focus on security: how an organization can successfully control privilege for all of the organization’s identities to mitigate identity-related risk without slowing down the business, and how Centrify provides ...
"Matrix is an ambitious open standard and implementation that's set up to break down the fragmentation problems that exist in IP messaging and VoIP communication," explained John Woolf, Technical Evangelist at Matrix, in this SYS-CON.tv interview at @ThingsExpo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today Isomorphic Software, the global leader in high-end, web-based business applications, will exhibit at SYS-CON's DevOps Summit 2015 New York, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Isomorphic Software is the global leader in high-end, web-based business applications. We develop, market, and support the SmartClient & Smart GWT HTML5/Ajax platform, combining the productivity and performance of traditional desktop software ...
DevOps Summit 2015 New York, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that it is now accepting Keynote Proposals. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that produce software that is obsolete...
The 3rd International @ThingsExpo, co-located with the 16th International Cloud Expo – to be held June 9-11, 2015, at the Javits Center in New York City, NY – is now accepting Hackathon proposals. Hackathon sponsorship benefits include general brand exposure and increasing engagement with the developer ecosystem. At Cloud Expo 2014 Silicon Valley, IBM held the Bluemix Developer Playground on November 5 and ElasticBox held the DevOps Hackathon on November 6. Both events took place on the expo fl...
We are reaching the end of the beginning with WebRTC, and real systems using this technology have begun to appear. One challenge that faces every WebRTC deployment (in some form or another) is identity management. For example, if you have an existing service – possibly built on a variety of different PaaS/SaaS offerings – and you want to add real-time communications you are faced with a challenge relating to user management, authentication, authorization, and validation. Service providers will w...
There's Big Data, then there's really Big Data from the Internet of Things. IoT is evolving to include many data possibilities like new types of event, log and network data. The volumes are enormous, generating tens of billions of logs per day, which raise data challenges. Early IoT deployments are relying heavily on both the cloud and managed service providers to navigate these challenges. In her session at Big Data Expo®, Hannah Smalltree, Director at Treasure Data, discussed how IoT, Big D...
The Internet of Things is tied together with a thin strand that is known as time. Coincidentally, at the core of nearly all data analytics is a timestamp. When working with time series data there are a few core principles that everyone should consider, especially across datasets where time is the common boundary. In his session at Internet of @ThingsExpo, Jim Scott, Director of Enterprise Strategy & Architecture at MapR Technologies, discussed single-value, geo-spatial, and log time series dat...
The Internet of Things will put IT to its ultimate test by creating infinite new opportunities to digitize products and services, generate and analyze new data to improve customer satisfaction, and discover new ways to gain a competitive advantage across nearly every industry. In order to help corporate business units to capitalize on the rapidly evolving IoT opportunities, IT must stand up to a new set of challenges. In his session at @ThingsExpo, Jeff Kaplan, Managing Director of THINKstrateg...
Fundamentally, SDN is still mostly about network plumbing. While plumbing may be useful to tinker with, what you can do with your plumbing is far more intriguing. A rigid interpretation of SDN confines it to Layers 2 and 3, and that's reasonable. But SDN opens opportunities for novel constructions in Layers 4 to 7 that solve real operational problems in data centers. "Data center," in fact, might become anachronistic - data is everywhere, constantly on the move, seemingly always overflowing. Net...